GMMMG Consultations

On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below.

Due to the COVID-19 outbreak all active GMMMG consultations were temporarily suspended in April. The active consultations have now been re-opened; please see below for the new end dates. Every effort has been made to allow sufficient time for appropriate clinical input to these documents, but if you foresee any problems or have any questions please email nuth.enquires.gmmmg@nhs.net

Title

Information

Feedback

End date

99

GMMMG Clinical Reference Group- actions proposed at November’s meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on actions proposed at the November meeting. This consultation period is open until 5pm Thursday 31st December 2020.

Feedback Form

5pm Thursday
31st December 2020

98

GMMMG Implementation Group- Gabapentinoids Resource Pack

On behalf of the GMMMG Implementation Group,  we now seek comments on a new GMMMG Resource Pack for Gabapentinoid Prescribing for Pain. This resource pack aims to support safe and evidence-based prescribing, review and deprescribing of gabapentin and pregabalin in the treatment of pain. This consultation period is open until 5pm Wednesday 9th December 2020.

Feedback Form

5pm Wednesday
9th December 2020

97

GMMMG Clinical Reference Group- actions proposed at September’s meeting

On behalf of the GMMMG Clinical Reference Group,  we now seek comments on actions proposed at the September meeting. This consultation period is open until 5pm Tuesday 8th December 2020.

Feedback Form

5pm Tuesday
8th December 2020

96

Review of GMMMG shared care protocols, processes around transfer of prescribing responsibilities to primary care, and RAG criteria
(this is a zipped file containing three documents)

The GMMMG Clinical Reference and Implementation Groups are undertaking a review of GMMMG shared care protocols, processes around transfer of prescribing responsibilities to primary care, and RAG criteria. This is in line with GMMMG priorities for 2020/21.

We now seek comments on three key aspects that underpin this work:

• Updated Guidelines on Defining Red, Amber and Green Medicine Status
• New Guidance on the Transfer of Prescribing Responsibilities to Primary Care
• Updated Shared Care Protocol (SCP) Template- Azathioprine in Adults has been provided as an example

Comments from all sectors are welcomed, particularly from colleagues who are familiar with current shared care arrangements and/ or prescribing across the interface.

This consultation is open until 5pm Friday 27th November.

Feedback Form

 5pm Friday
27th November 2020